Literature DB >> 24005375

CD4⁺CD73⁺ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression.

Patrick J Schuler1, Bernard J C Macatangay, Zenichiro Saze, Edwin K Jackson, Sharon A Riddler, William G Buchanan, Benedict B Hilldorfer, John W Mellors, Theresa L Whiteside, Charles R Rinaldo.   

Abstract

BACKGROUND: The role of the adenosine (ADO) suppression pathway, specifically CD39-expressing and CD73-expressing CD4⁺ T cells in HIV-1 infection is unclear.
METHODS: We evaluated the frequency and numbers of CD4CD39⁺ and CD4CD73⁺ T cells, activated T cells, and plasma C reactive protein (CRP) levels in 36 HIV-1-positive individuals and 10 normal controls (NC). Low-level plasma viremia was evaluated using single copy assay. Mass spectrometry was used to measure hydrolysis of ATP by ectoenzyme-expressing CD4⁺ T cells, whereas cyclic adenosine monophosphate (cAMP) levels were measured using enzyme immunoassay. Suppression of T-cell function by exogenous ADO and CD4CD73⁺ T cells was tested by flow cytometry.
RESULTS: CD39 and CD73 are expressed in different CD4⁺ T-cell subsets. CD4CD73⁺ T cells do not express CD25 and FOXP3, and their frequency and numbers were lower in HIV-1-positive individuals regardless of virologic suppression (P=0.005 and P<0.001, respectively). CD4CD73⁺ numbers inversely correlated with CD4CD38⁺DR⁺ (P=0.002), CD8CD38⁺DR⁺ T-cell frequency (P=0.05), and plasma CRP levels (P=0.01). Both subsets are required for hydrolysis of exogenous ATP to ADO and can increase CD4⁺ T-cell cAMP levels when incubated with exogenous ATP. Low-level viremia did not correlate with activated T-cell frequency. In vitro, ADO suppressed T-cell activation and cytokine expression. CD4CD7⁺ T cells suppressed T-cell proliferation only in the presence of exogenous 5'-AMP.
CONCLUSION: The ADO-producing CD4CD73⁺ subset of T cells is depleted in HIV-1-positive individuals regardless of viral suppression and may play a key role in controlling HIV-1-associated immune activation.
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24005375      PMCID: PMC3939796          DOI: 10.1097/QAD.0b013e328360c7f3

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  39 in total

Review 1.  Cardiovascular manifestations of HIV infection.

Authors:  Jennifer E Ho; Priscilla Y Hsue
Journal:  Heart       Date:  2009-07       Impact factor: 5.994

2.  Relative risk of death in the SMART study.

Authors:  Birgit Grund; Jacqueline Neuhaus; Andrew Phillips
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

3.  Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism.

Authors:  Maria E Moreno-Fernandez; Cesar Mauricio Rueda; Laura K Rusie; Claire A Chougnet
Journal:  Blood       Date:  2011-03-23       Impact factor: 22.113

4.  Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function.

Authors:  C T Burton; S J Westrop; I Eccles-James; A Boasso; M R Nelson; M Bower; N Imami
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

5.  Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity.

Authors:  W G Gutheil; M Subramanyam; G R Flentke; D G Sanford; E Munoz; B T Huber; W W Bachovchin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

6.  CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7.

Authors:  Marta Catalfamo; Christopher Wilhelm; Lueng Tcheung; Michael Proschan; Travis Friesen; Jung-Hyun Park; Joseph Adelsberger; Michael Baseler; Frank Maldarelli; Richard Davey; Gregg Roby; Catherine Rehm; Clifford Lane
Journal:  J Immunol       Date:  2011-01-21       Impact factor: 5.422

Review 7.  Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.

Authors:  Silvia Deaglio; Simon C Robson
Journal:  Adv Pharmacol       Date:  2011

8.  Crystal structures of HIV-1 Tat-derived nonapeptides Tat-(1-9) and Trp2-Tat-(1-9) bound to the active site of dipeptidyl-peptidase IV (CD26).

Authors:  Wilhelm Andreas Weihofen; Jianguo Liu; Werner Reutter; Wolfram Saenger; Hua Fan
Journal:  J Biol Chem       Date:  2005-01-28       Impact factor: 5.157

9.  Molecular mechanisms of treg-mediated T cell suppression.

Authors:  Angelika Schmidt; Nina Oberle; Peter H Krammer
Journal:  Front Immunol       Date:  2012-03-21       Impact factor: 7.561

10.  CD39/adenosine pathway is involved in AIDS progression.

Authors:  Maria Nikolova; Matthieu Carriere; Mohammad-Ali Jenabian; Sophie Limou; Mehwish Younas; Ayrin Kök; Sophie Huë; Nabila Seddiki; Anne Hulin; Olivier Delaneau; Hanneke Schuitemaker; Joshua T Herbeck; James I Mullins; Maria Muhtarova; Armand Bensussan; Jean-François Zagury; Jean-Daniel Lelievre; Yves Lévy
Journal:  PLoS Pathog       Date:  2011-07-07       Impact factor: 6.823

View more
  27 in total

Review 1.  Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: From viral entry to therapy.

Authors:  Daniela F Passos; Maria Rosa C Schetinger; Daniela Br Leal
Journal:  World J Virol       Date:  2015-08-12

2.  Critical Role for the Adenosine Pathway in Controlling Simian Immunodeficiency Virus-Related Immune Activation and Inflammation in Gut Mucosal Tissues.

Authors:  Tianyu He; Egidio Brocca-Cofano; Delbert G Gillespie; Cuiling Xu; Jennifer L Stock; Dongzhu Ma; Benjamin B Policicchio; Kevin D Raehtz; Charles R Rinaldo; Cristian Apetrei; Edwin K Jackson; Bernard J C Macatangay; Ivona Pandrea
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

3.  Immune Activation and Inflammation in People With Human Immunodeficiency Virus: Challenging Targets.

Authors:  Netanya S Utay; Edgar T Overton
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

Review 4.  Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection.

Authors:  Daniela F Passos; Viviane M Bernardes; Jean L G da Silva; Maria R C Schetinger; Daniela Bitencourt Rosa Leal
Journal:  Purinergic Signal       Date:  2018-08-10       Impact factor: 3.765

5.  A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation.

Authors:  Bernard J C Macatangay; Edwin K Jackson; Kaleab Z Abebe; Diane Comer; Joshua Cyktor; Cynthia Klamar-Blain; Luann Borowski; Delbert G Gillespie; John W Mellors; Charles R Rinaldo; Sharon A Riddler
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

6.  Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV.

Authors:  Theresa L Whiteside
Journal:  Cancer Microenviron       Date:  2014-11-12

Review 7.  [B cells in head and neck oncology].

Authors:  P J Schuler; C Brunner; T K Hoffmann
Journal:  HNO       Date:  2018-04       Impact factor: 1.284

8.  Subclinical herpesvirus shedding among HIV-1-infected men on antiretroviral therapy.

Authors:  Arcadio Agudelo-Hernandez; Yue Chen; Arlene Bullotta; William G Buchanan; Cynthia R Klamar-Blain; Luann Borowski; Sharon A Riddler; Charles R Rinaldo; Bernard J C Macatangay
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

Review 9.  Induced regulatory T cells in inhibitory microenvironments created by cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2014-06-17       Impact factor: 4.388

10.  Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.

Authors:  P J Schuler; Z Saze; C-S Hong; L Muller; D G Gillespie; D Cheng; M Harasymczuk; M Mandapathil; S Lang; E K Jackson; T L Whiteside
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.